These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 22341702

  • 1. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L, Prestinenzi P, Bianchi IG, Masetti M, Romani P, Magnani G, Fallani F, Coccolo F, Russo A, Ponticelli C, Rapezzi C, Grigioni F, Branzi A.
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [Abstract] [Full Text] [Related]

  • 2. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 3. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.
    Transplant Proc; 2013 Jul 15; 45(6):2387-92. PubMed ID: 23953553
    [Abstract] [Full Text] [Related]

  • 4. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Mai D, Dandel M, Knosalla C, Hiemann NE, Grauhan O, Huebler M, Pasic M, Weng Y, Meyer R, Rothenburger M, Hummel M, Hetzer R.
    J Heart Lung Transplant; 2007 Jul 15; 26(7):700-4. PubMed ID: 17613400
    [Abstract] [Full Text] [Related]

  • 5. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 15; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 6. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
    Wang SS, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY, Huang SC, Wang CH, Ko WJ, Tsao CI, Sun CD.
    Transplant Proc; 2008 Oct 15; 40(8):2607-8. PubMed ID: 18929814
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
    Potena L, Bianchi IG, Magnani G, Masetti M, Coccolo F, Fallani F, Russo A, Grigioni F, Branzi A, Ponticelli C.
    Transplantation; 2010 Jan 27; 89(2):263-5. PubMed ID: 20098293
    [No Abstract] [Full Text] [Related]

  • 8. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H, B251 Study Group.
    Transplantation; 2005 Jul 27; 80(2):244-52. PubMed ID: 16041270
    [Abstract] [Full Text] [Related]

  • 9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 27; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 10. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
    Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, Shun CT.
    Transplant Proc; 2010 Apr 27; 42(3):938-9. PubMed ID: 20430209
    [Abstract] [Full Text] [Related]

  • 11. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Apr 27; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 12. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.
    Transplantation; 2013 Feb 27; 95(4):629-34. PubMed ID: 23423270
    [Abstract] [Full Text] [Related]

  • 13. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 27; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 14. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 27; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 15. Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients.
    Manito N, Rábago G, Palomo J, Arizón JM, Delgado J, Almenar L, Crespo-Leiro MG, Lage E, Pulpón L.
    Transplant Proc; 2011 Sep 27; 43(7):2699-706. PubMed ID: 21911149
    [Abstract] [Full Text] [Related]

  • 16. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
    Michel S, Bigdeli AK, Hagl C, Meiser B, Kaczmarek I.
    Exp Clin Transplant; 2013 Oct 27; 11(5):429-34. PubMed ID: 24128136
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D, Silva HT, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS.
    Transplantation; 2013 Apr 15; 95(7):933-42. PubMed ID: 23422495
    [Abstract] [Full Text] [Related]

  • 18. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
    Sheshgiri R, Gustafsson F, Sheedy J, Rao V, Ross HJ, Delgado DH.
    J Heart Lung Transplant; 2009 Nov 15; 28(11):1193-7. PubMed ID: 19783164
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May 15; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 20. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L, Ding T, Wang XX, Lin ZB, Chen G.
    Zhonghua Yi Xue Za Zhi; 2016 May 31; 96(20):1556-61. PubMed ID: 27266681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.